Brainsway Ltd. American Depositary Shares

BrainsWay Ltd., a leader in noninvasive neurostimulation technologies, announced it will report first quarter 2026 financial results on May 13, 2026, with a conference call at 8:30 AM ET. The company highlighted growing U.S. payer support for nurse practitioner-administered TMS therapy and will participate in the Needham Virtual Healthcare Confer...

BrainsWay Ltd., a leader in noninvasive neurostimulation technologies, announced it will report fourth quarter and full year 2025 financial results on March 11, 2026, with a conference call at 8:30 AM ET. The company will discuss results and provide operational updates.

BrainsWay received FDA clearance to use Deep TMS™ as an adjunct therapy for major depressive disorder in adolescents aged 15-21, based on a comprehensive dataset of 1,120 patients showing significant symptom improvement and safety.

BrainsWay received a $2.5 million NIH grant for a clinical study investigating an accelerated Deep Transcranial Magnetic Stimulation protocol to treat Alcohol Use Disorder, led by Stanford University researchers.

BrainsWay, a neurostimulation treatment company, will report its third quarter 2025 financial results on November 11, 2025, hosting a conference call to discuss financial performance and business operations.